Global Atrophie Biomarker Evaluation Study (GABiE)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

3 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-07

Study Completion Date

2020-05-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the use of microperimetry and SS-OCT in assessing the natural changes of retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in patients with dry age-related macular degeneration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study

NCT05963646

COMPLETED

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

NCT05797896

ACTIVE_NOT_RECRUITING

Sparing of the Fovea in Geographic Atrophy Progression

NCT02332343

Atrophy Geographic Atrophy Age-related Macular Degeneration +1 more

COMPLETED

Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration

NCT02941263

Age-Related Macular Degeneration

COMPLETED

Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device

NCT02445313

Age-related Macular Degeneration (AMD)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age-related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All patients

Diagnostics

Intervention Type DIAGNOSTIC_TEST

Diagnostics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnostics

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the study
* Age \>=60 years
* Ability (including a sufficient general health status according to investigators judgement) and willingness to undertake all scheduled visits and assessments including predefined methodology and standards utilizing microperimetry GA secondary to AMD with no evidence of prior or active choroidal neovascularization (CNV) in the study eye
* GA lesion in the study eye must reside completely within the FAF imaging field (Field 2- 30 degree image centered on the fovea)
* BCVA of 20/63 or better (Snellen equivalent) using ETDRS charts at starting distance of 4 m in the study eye
* Well demarcated area(s) of GA secondary to AMD with no evidence of prior or active CNV in the study eye

* The total GA lesion size \>=1.2 mm\^2 (approximately \>=0.5 disc area \[DA\]) and \<=17.78 mm\^2 (approximately \<=7 DA) and must reside completely within the FAF imaging field (Field 2-30 degree image centered on the fovea)
* If GA is multifocal, at least 1 focal lesion must be \>=1.2 mm\^2 (approximately \>=0.5 DA)
* Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging in the study eye

Exclusion Criteria

* GA in either eye due to causes other than AMD (for example, monogenetic macular dystrophies \[e.g., Stargardt disease, cone rod dystrophy\] or toxic maculopathies \[e.g., chloroquine/hydroxychloroquine maculopathy\])
* Receiving active treatment in any studies of investigational drugs for GA/dry AMD in the study eye
* Mean sensitivity difference \> 3 dB between the two microperimetry examinations in the screening visit.
* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye
* Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and proliferative diabetic retinopathy in the study eye
* Prior treatment with Visudyne ®, external-beam radiation therapy, or transpupillary thermotherapy in the study eye
* History of prophylactic subthreshold laser treatment for AMD in the study eye
* Further criteria apply.

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No